ArticleResearch square2026
Statin Use and Primary Open-Angle Glaucoma Severity in Patients of African Ancestry.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Objective: The evidence supporting the benefit of statins in the treatment of primary open-angle glaucoma (POAG) is mixed, and their effect among patients of African ancestry is largely unexplored. This study examines the association of statins with the prevalence and severity of POAG in this ancestry group. Design: Cross-sectional study. Subjects: 5715 subjects of African ancestry (African American, African descent, or African Caribbean) ages 35 and older, recruited from ophthalmology clinics in the University of Pennsylvania Health System as part of the Primary Open-Angle African Ancestry Glaucoma Genetics (POAAGG) study. Methods: Logistic regression was used to analyze the prevalence of POAG in statin users versus non-users, adjusting for demographic and clinical co-variates. Sub-analyses compared POAG prevalence between high-potency and low-potency statin users. Ocular endophenotypes were compared between statin users and non-users. Main Outcome Measures: POAG prevalence, ocular endophenotypes. Results: POAG prevalence did not differ between statin users and non-users (OR: 0.99, 95% CI: 0.85, 1.14; p = 0.84). Among POAG cases, statin users had significantly smaller mean cup-to-disc ratio (mean difference [MD]=-0.03, 95% CI: -0.04, -0.01, p < 0.001), better visual acuity (MD=-0.10, 95% CI: -0.16, -0.04, p = 0.001), thicker mean retinal nerve fiber layers (MD = 1.43, 95% CI: 0.18, 2.68, p = 0.03), and lower mean pattern standard deviation values (MD=-0.39, 95% CI: -0.66, -0.13, p = 0.004) than non-users. Conclusion: Statin use was not associated with POAG prevalence but was associated with milder structural and functional disease features among cases. These findings suggest the need for further investigation of the effect of statins in African ancestry patients with POAG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.